Wörns MA - Search Results

1

Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. Bitzer M, et al. Among authors: worns ma. J Hepatol. 2016 Aug;65(2):280-8. doi: 10.1016/j.jhep.2016.02.043. Epub 2016 Mar 4. J Hepatol. 2016. PMID: 26952006 Clinical Trial.

2

Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.

Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR. Wörns MA, et al. J Clin Gastroenterol. 2009 May-Jun;43(5):489-95. doi: 10.1097/MCG.0b013e31818ddfc6. J Clin Gastroenterol. 2009. PMID: 19247201

3

Systemic therapies in hepatocellular carcinoma.

Wörns MA, Weinmann A, Schuchmann M, Galle PR. Wörns MA, et al. Dig Dis. 2009;27(2):175-88. doi: 10.1159/000218351. Epub 2009 Jun 22. Dig Dis. 2009. PMID: 19546557 Review.

4

Novel inhibitors in development for hepatocellular carcinoma.

Wörns MA, Galle PR. Wörns MA, et al. Expert Opin Investig Drugs. 2010 May;19(5):615-29. doi: 10.1517/13543781003767418. Expert Opin Investig Drugs. 2010. PMID: 20374038 Review.

5

Future perspectives in hepatocellular carcinoma.

Wörns MA, Galle PR. Wörns MA, et al. Dig Liver Dis. 2010 Jul;42 Suppl 3:S302-9. doi: 10.1016/S1590-8658(10)60521-X. Dig Liver Dis. 2010. PMID: 20547319 Review.

6

Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.

Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A. Wörns MA, et al. Oncology. 2010;79(1-2):85-92. doi: 10.1159/000320363. Epub 2010 Nov 12. Oncology. 2010. PMID: 21071995

7

Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo.

Schattenberg JM, Zimmermann T, Wörns M, Sprinzl MF, Kreft A, Kohl T, Nagel M, Siebler J, Schulze Bergkamen H, He YW, Galle PR, Schuchmann M. Schattenberg JM, et al. J Hepatol. 2011 Dec;55(6):1272-80. doi: 10.1016/j.jhep.2011.03.008. Epub 2011 Apr 15. J Hepatol. 2011. PMID: 21703207

8

Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver.

Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, Hansen T, Pitton MB, Niederle IM, Schuchmann M, Weinmann A, Düber C, Galle PR, Otto G. Wörns MA, et al. Scand J Gastroenterol. 2012 Jun;47(6):718-28. doi: 10.3109/00365521.2012.677952. Epub 2012 Apr 4. Scand J Gastroenterol. 2012. PMID: 22472070

9

Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.

Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hövelmeyer N, Hahn M, Schuchmann M, Jäger D, Waisman A, Wörns MA, Schulze-Bergkamen H. Urbanik T, et al. Among authors: worns ma. J Hepatol. 2012 Nov;57(5):995-1003. doi: 10.1016/j.jhep.2012.06.017. Epub 2012 Jun 21. J Hepatol. 2012. PMID: 22728872

10

The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.

Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A. Wörns MA, et al. Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21. Dig Liver Dis. 2013. PMID: 23182599

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page